Add like
Add dislike
Add to saved papers

HEPATIC EPITHELIOID HEMANGIO-ENDOTHELIOMA AND ADULT LIVER TRANSPLANTATION: PROPOSAL FOR A PROGNOSTIC SCORE BASED ON THE ANALYSIS OF THE ELTR-ELITA REGISTRY.

Transplantation 2016 December 7
BACKGROUND: Hepatic epithelioid hemangio-endothelioma (HEHE) is a rare vascular tumor which has an intermediate aggressive behavior. Although the value of liver transplantation (LT) is well established, its place in the management of HEHE is still unclear. The aim of this study is to confirm, based on a very large patient cohort, the value of LT in the management of HEHE and to identify risk factors for post-LT recurrence.

MATERIAL AND METHODS: the outcome of 149 transplant recipients with HEHE recorded in the European Liver Transplant Registry during the period November1984-May 2014 was analyzed. Median post-LT follow-up was 7.6 years (IQR=2.8-14.4).

RESULTS: Cox regression analysis showed that macro-vascular invasion (hazard ratio=4.8; p<0.001), pre-LT waiting-time ≤120 days (HR=2.6; p=0.01) and hilar lymph-node invasion (HR=2.2; p=0.03), but not pre-LT extra-hepatic disease (EHD), were significant risk factors for recurrence. These findings, which were also confirmed in a propensity score analysis, allowed the development of a HEHE-LT score enabling stratification of patients in relation to their risk of tumor recurrence. Patients with a score of ≤2 had a much better 5-year disease-free survival compared to those having a score of ≥6 (93.9 vs. 38.5%; p<0.001).

CONCLUSIONS: The analysis of this (largest in the world) HEHE adult liver recipient cohort clearly confirms the value of LT in the treatment of this rare disorder and also permits identification of patients at risk of posttransplant recurrence. Posttransplant follow-up should be take the HEHE-LT score into account. EHD localization is re-confirmed not to be a contraindication for LT.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app